CU22584A1 - Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis - Google Patents

Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis

Info

Publication number
CU22584A1
CU22584A1 CU1995120A CU1995120A CU22584A1 CU 22584 A1 CU22584 A1 CU 22584A1 CU 1995120 A CU1995120 A CU 1995120A CU 1995120 A CU1995120 A CU 1995120A CU 22584 A1 CU22584 A1 CU 22584A1
Authority
CU
Cuba
Prior art keywords
pharmaceutical compositions
monoclonal antibody
recognizes
psoriasis
compositions containing
Prior art date
Application number
CU1995120A
Other languages
English (en)
Inventor
Blazquez Patricia Sierra
Valladares Josefa Lombardero
Casimiro Jose Enrique Montero
Bravo Blanca Rosa Tormo
Rodriguez Rolando Perez
Original Assignee
Centro Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro Inmunologia Molecular filed Critical Centro Inmunologia Molecular
Priority to CU1995120A priority Critical patent/CU22584A1/es
Priority to DK96939805T priority patent/DK0807125T3/da
Priority to US08/875,674 priority patent/US6572857B1/en
Priority to AU76905/96A priority patent/AU722882B2/en
Priority to CNB96192098XA priority patent/CN1222540C/zh
Priority to ES96939805T priority patent/ES2231826T3/es
Priority to PT96939805T priority patent/PT807125E/pt
Priority to PCT/CU1996/000004 priority patent/WO1997019111A2/es
Priority to DE69633717T priority patent/DE69633717T2/de
Priority to EP96939805A priority patent/EP0807125B1/en
Priority to CA002210751A priority patent/CA2210751C/en
Priority to AT96939805T priority patent/ATE280783T1/de
Priority to KR1019970704893A priority patent/KR100533854B1/ko
Priority to BRPI9607171A priority patent/BRPI9607171B1/pt
Priority to JP51926797A priority patent/JP4113929B2/ja
Priority to MXPA/A/1997/005445A priority patent/MXPA97005445A/es
Publication of CU22584A1 publication Critical patent/CU22584A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/205—Scaling palpular diseases, e.g. psoriasis, pytiriasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se relaciona con la rama de la Inmunología y en particular con la obtención de composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario CD6. De acuerdo con lo expuesto, el objeto de esta invención es proporcionar composiciones farmacéuticas que contengan un anticuerpo monoclonal anti CD6 para el diagnóstico y tratamiento de lesiones cutáneas de la Psoriasis Vulgar. La esencia de la invención consiste en aplicar un anticuerpo monoclonal que reconoce el antígeno CD&, obtener composiciones farmacéuticas que contengan este anticuerpo y sean capaces de lograr una efectividad clínica e histológica en pacientes con las diferentes formas clínicas de la Psoriasis. El campo de aplicación de la presente invención se extiende a la Dermatología.
CU1995120A 1995-11-17 1995-11-17 Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis CU22584A1 (es)

Priority Applications (16)

Application Number Priority Date Filing Date Title
CU1995120A CU22584A1 (es) 1995-11-17 1995-11-17 Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis
DK96939805T DK0807125T3 (da) 1995-11-17 1996-11-18 Monoklonale antistoffer mod CD6 til behandling og diagnosticering af psoriasis
US08/875,674 US6572857B1 (en) 1995-11-17 1996-11-18 Anti-CD6 monoclonal antibodies and their uses
AU76905/96A AU722882B2 (en) 1995-11-17 1996-11-18 Anti-CD6 monoclonal antibodies and their uses
CNB96192098XA CN1222540C (zh) 1995-11-17 1996-11-18 抗cd6的单克隆抗体和它们的用途
ES96939805T ES2231826T3 (es) 1995-11-17 1996-11-18 Anticuerpos monoclonales anti-cd6 para el tratamiento y el diagnostico de la psoriasis.
PT96939805T PT807125E (pt) 1995-11-17 1996-11-18 Anticorpos monoclonais anti-cd6 para o tratamento e diagnose da psoriase
PCT/CU1996/000004 WO1997019111A2 (es) 1995-11-17 1996-11-18 Anticuerpos monoclonales anti-cd6 y sus utilizaciones
DE69633717T DE69633717T2 (de) 1995-11-17 1996-11-18 Monoklonale anti-cd6 antikörper zur behandlung und diagnose von psoriasis
EP96939805A EP0807125B1 (en) 1995-11-17 1996-11-18 Monoclonal antibodies anti-cd6 for the treatment and diagnosis of psoriasis
CA002210751A CA2210751C (en) 1995-11-17 1996-11-18 Anti-cd6 monoclonal antibodies and their uses
AT96939805T ATE280783T1 (de) 1995-11-17 1996-11-18 Monoklonale anti-cd6 antikörper zur behandlung und diagnose von psoriasis
KR1019970704893A KR100533854B1 (ko) 1995-11-17 1996-11-18 항-cd6 단일클론항체 및 이를 포함하는 건선치료용 약제조성물
BRPI9607171A BRPI9607171B1 (pt) 1995-11-17 1996-11-18 anticorpo monoclonal anti-cd6 humano, usos dos mesmos para o diagnóstico in vitro de psoríase, composição farmacêutica e reagente contendo o dito anticorpo
JP51926797A JP4113929B2 (ja) 1995-11-17 1996-11-18 アンチｃｄ６モノクロナール抗体とその利用
MXPA/A/1997/005445A MXPA97005445A (es) 1995-11-17 1997-07-17 Anticuerpos monoclonales anti-cd6 y sus usos

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU1995120A CU22584A1 (es) 1995-11-17 1995-11-17 Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis

Publications (1)

Publication Number Publication Date
CU22584A1 true CU22584A1 (es) 1999-11-03

Family

ID=5459401

Family Applications (1)

Application Number Title Priority Date Filing Date
CU1995120A CU22584A1 (es) 1995-11-17 1995-11-17 Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis

Country Status (15)

Country Link
US (1) US6572857B1 (es)
EP (1) EP0807125B1 (es)
JP (1) JP4113929B2 (es)
KR (1) KR100533854B1 (es)
CN (1) CN1222540C (es)
AT (1) ATE280783T1 (es)
AU (1) AU722882B2 (es)
BR (1) BRPI9607171B1 (es)
CA (1) CA2210751C (es)
CU (1) CU22584A1 (es)
DE (1) DE69633717T2 (es)
DK (1) DK0807125T3 (es)
ES (1) ES2231826T3 (es)
PT (1) PT807125E (es)
WO (1) WO1997019111A2 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003534022A (ja) * 2000-05-26 2003-11-18 スミスクライン・ビーチャム・コーポレイション Ｒａｎｋリガンド介在障害の治療に有用な抗−ｒａｎｋリガンドモノクローナル抗体
CU23097A1 (es) 2002-10-23 2005-11-18 Centro Inmunologia Molecular Método para la obtención de líneas celulares en medio libre de proteína y líneas celulares obtenidas por este método
US20070003568A1 (en) 2003-02-24 2007-01-04 Alice Dautry-Varsat Secreted chlamydia polypeptides, polynucleotides coding therefor, therapeutic and diagnostic uses thereof
WO2008077355A1 (es) * 2006-12-26 2008-07-03 Centro De Inmunolgía Molecular Composición farmaceutica que comprende un anticuerpo monoclonal anti-cd6 utilizado en el diagnóstico y tratamiento de la artritis reumatoide
ES2542861T3 (es) * 2006-12-26 2015-08-12 Centro De Inmunolgía Molecular Composiciones farmacéuticas capaces de inducir la apoptosis en células tumorales, útiles para el diagnóstico y tratamiento de leucemia linfocítica crónica-B
SI2242769T1 (sl) 2008-01-11 2017-02-28 Adheron Therapeutics, Inc. Protitelesa anti-kadherin-11 EC domene za zdravljenje vnetnih obolenj sklepov
CA2716919C (en) 2008-03-14 2015-01-20 Biocon Limited An anti-cd6 monoclonal antibody and use thereof
CN103153331B (zh) * 2010-07-15 2017-03-22 亚德赫伦医疗公司 靶向于钙粘着蛋白‑11的ec1结构域的人源化抗体及相关组合物和方法
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
LT4108671T (lt) 2010-10-01 2025-01-10 Modernatx, Inc. Modifikuoti nukleozidai, nukleotidai, nukleorūgštys bei jų panaudojimas
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
BR112013033988B1 (pt) 2011-07-01 2021-10-19 Beckman Coulter, Inc. Métodos de identificação e isolamento de uma ou mais populações de células t regulatórias imunossupressoras
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
SMT202200229T1 (it) 2011-10-03 2022-07-21 Modernatx Inc Nucleosidi, nucleotidi e acidi nucleici modificati e loro usi
RU2649364C2 (ru) 2011-12-16 2018-04-02 Модерна Терапьютикс, Инк. Составы на основе модифицированного нуклеозида, нуклеотида и нуклеиновой кислоты
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
AU2013243954A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
HRP20220607T1 (hr) 2012-11-26 2022-06-24 Modernatx, Inc. Terminalno modificirana rna
FR3000216B1 (fr) * 2012-12-21 2015-02-06 Galderma Res & Dev Utilisation de proteases particulieres pour la detection de trichophytons et de pathologies associees
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
KR102276745B1 (ko) 2013-07-23 2021-07-14 바이오콘 리미티드 Cd6 결합 파트너의 용도 및 이에 기초한 방법
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
BR112016007255A2 (pt) 2013-10-03 2017-09-12 Moderna Therapeutics Inc polinucleotídeos que codificam receptor de lipoproteína de baixa densidade
CN105504062B (zh) * 2015-12-25 2019-06-04 百泰生物药业有限公司 一种抗CD6单抗T1h的检测性抗体及应用
JP7071974B2 (ja) * 2016-10-21 2022-05-19 バイオコン・リミテッド モノクローナル抗体および狼瘡の処置のための使用の方法
WO2019169015A1 (en) * 2018-02-27 2019-09-06 Equillium, Inc. Anti cd6 antibodies for treating severe asthma
US12281151B2 (en) 2018-06-29 2025-04-22 City Of Hope CD6 targeted chimeric antigen receptors for treatment of certain autoimmune disorders
PH12021551994A1 (en) 2019-02-26 2022-08-15 Equillium Inc Anti-cd6 antibody compositions and methods for treating lupus
US20230076643A1 (en) 2019-12-30 2023-03-09 City Of Hope Methods of making and using regulatory t cells and effector t cells having chimeric antigen receptors targeted to cd6, cd19, and/or an il-13r for treatment of autoimmune disorders and cancers
US20230151107A1 (en) * 2020-04-04 2023-05-18 Biocon Limited Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19
AU2022344418A1 (en) 2021-09-08 2024-04-04 Centro De Inmunologia Molecular Use of anti-cd6 monoclonal antibodies in the prevention of cellular and organ damage resulting from hyper- inflammatory response
WO2025096685A1 (en) 2023-10-30 2025-05-08 City Of Hope Methods of making and using regulatory t cells for treatment of autoimmune disorders and cancers
CN120005027B (zh) * 2025-04-10 2025-09-23 中国水产科学研究院长江水产研究所 大口黑鲈cd6抗原结合肽、及其单克隆抗体和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2175247A1 (en) * 1993-11-02 1995-05-11 Barton F. Haynes Cd6 ligand
CU22615A1 (es) * 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos

Also Published As

Publication number Publication date
BRPI9607171B1 (pt) 2016-07-19
KR100533854B1 (ko) 2006-09-20
PT807125E (pt) 2005-03-31
DK0807125T3 (da) 2005-03-14
MX9705445A (es) 1998-06-30
DE69633717D1 (de) 2004-12-02
BR9607171A (pt) 1997-11-11
CN1175957A (zh) 1998-03-11
EP0807125B1 (en) 2004-10-27
WO1997019111A3 (es) 1998-02-12
AU722882B2 (en) 2000-08-10
CA2210751C (en) 2007-01-30
WO1997019111A2 (es) 1997-05-29
ES2231826T3 (es) 2005-05-16
CN1222540C (zh) 2005-10-12
KR19980701502A (ko) 1998-05-15
EP0807125A2 (en) 1997-11-19
JP4113929B2 (ja) 2008-07-09
AU7690596A (en) 1997-06-11
CA2210751A1 (en) 1997-05-29
DE69633717T2 (de) 2006-02-02
US6572857B1 (en) 2003-06-03
ATE280783T1 (de) 2004-11-15
JPH11506017A (ja) 1999-06-02

Similar Documents

Publication Publication Date Title
CU22584A1 (es) Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis
CU23251A3 (es) Formulaciones liquidas estables de toxina botulinica
FR2810539B1 (fr) Procede et dispositif de traitement,notamment de maquillage, de coloration ou de soin cosmetique,de parties ou de la totalite du corps humain ou animal
Van Praag et al. Determination of the photoprotective efficacy of a topical sunscreen against UVB-induced DNA damage in human epidermis
UY27242A1 (es) Anticuerpos recombinantes asociados a gangliosidos. su uso en el diasnostico y tratamiento de tumores
Murphy et al. Sunbed‐induced pseudoporphyria
Nestor et al. Efficacy and tolerability of a combined 445nm and 630nm over-the-counter light therapy mask with and without topical salicylic acid versus topical benzoyl peroxide for the treatment of mild-to-moderate acne vulgaris
Giehl et al. A controlled trial of photodynamic therapy of actinic keratosis comparing different red light sources
DK0709097T3 (da) Anti-Fas antistof mod reumatiske sygdomme
Giovinazzo et al. Photoallergic contact dermatitis to musk ambrette: histopathologic features of photobiologic reactions observed in a persistent light reactor
Cantisani et al. Daylight-photodynamic therapy for the treatment of actinic keratosis in different seasons
Calin et al. Photosensitizers and light sources for photodynamic therapy of the Bowen’s disease
Lamberg Symptomatic pitted keratolysis
Verma et al. Idiopathic'Half and half'nails.
AR004355A1 (es) Anticuerpos monoclonales anti-cd6 y sus usos.
ES2161987T3 (es) Parche/pelicula radioactiva y procedimiento para la preparacion de la misma.
Jiyad et al. Handbook of Skin Disease Management
BR9504089A (pt) Agente para o tratamento ou cuidado de pele irritada ou inflamada e aplicação
BR9911904A (pt) Processo cosmético para a redução ou prevenção do mau cheiro do corpo, e, uso de um agente ativo.
Taïeb et al. Management overview
Basdew et al. Adjunctive treatment of keloids: comparison of photodynamic therapy with brachytherapy
Eber et al. Photodynamic therapy
Willis Photosensitivity.
Conforti et al. A case of allergic contact dermatitis to dental bonding materials, masked by the use of gloves
Poh-Fitzpatrick The biologic actions of solar radiation on skin with a note on sunscreens